## Molecular epidemiology of recurrent zoonotic transmission of mpox virus in West Africa

Delia Doreen Djuicy<sup>\*1</sup>, Ifeanyi F. Omah<sup>\*2,3</sup>, Edyth Parker<sup>\*4,5</sup>, Christopher H Tomkins-Tinch<sup>6</sup>, James Richard Otieno<sup>7</sup>, Moïse Henri Moumbeket Yifomnjou<sup>1</sup>, Loique Landry Messanga Essengue<sup>1</sup>, Akeemat Opeyemi Ayinla<sup>4</sup>, Ayotunde E. Sijuwola<sup>4</sup>, Muhammad I. Ahmed<sup>4</sup>, Oludayo O. Ope-ewe<sup>4</sup>, Olusola Akinola Ogunsanya<sup>4</sup>, Alhaji Olono<sup>4</sup>, Philomena Eromon<sup>4</sup>, Martial Gides Wansi Yonga<sup>1</sup>, Gael Dieudonné Essima<sup>1</sup>, Ibrahim Pascal Touoyem<sup>1</sup>, Landry Jules Mouliem Mounchili<sup>1</sup>, Sara Irene Eyangoh<sup>1</sup>, Linda Esso<sup>8</sup>, Inès Mandah Emah Nguidjol<sup>8</sup>, Steve Franck Metomb<sup>8</sup>, Cornelius Chebo<sup>8</sup>, Samuel Mbah Agwe<sup>8</sup>, Hans Makembe Mossi<sup>8</sup>, Chanceline Ndongo Bilounga<sup>8</sup>, Alain Georges Mballa Etoundi<sup>1</sup>, Olusola Akanbi<sup>9</sup>, Abiodun Egwuenu<sup>9</sup>, Odianosen Ehiakhamen<sup>9</sup>, Chimaobi Chukwu<sup>9</sup>, Kabiru Suleiman<sup>9</sup>, Afolabi Akinpelu<sup>9</sup>, Adama Ahmad<sup>9</sup>, Khadijah Isa Imam<sup>9</sup>, Richard Ojedele<sup>9</sup>, Victor Oripenaye<sup>9</sup>, Kenneth Ikeata<sup>9</sup>, Sophiyah Adelakun<sup>9</sup>, Babatunde Olajumoke<sup>9</sup>, Áine O'Toole<sup>2</sup>, Andrew Magee<sup>10</sup>, Mark Zeller<sup>5</sup>, Karthik Gangavarapu<sup>5</sup>, Patrick Varilly<sup>6</sup>, Daniel J Park<sup>6</sup>, Gerald Mboowa<sup>11</sup>, Sofonias Kifle Tessema<sup>11</sup>, Yenew Kebede Tebeje<sup>11</sup>, Onikepe Folarin<sup>4,12</sup>, Anise Happi<sup>4</sup>, Philippe Lemey<sup>13</sup>, Marc A Suchard<sup>10,14,15</sup>, Kristian G. Andersen<sup>5,16</sup>, Pardis Sabeti<sup>6,17</sup>, Andrew Rambaut<sup>2</sup>, Chikwe Ihekweazu<sup>9</sup>, Idriss Jide<sup>9</sup>, Ifedayo Adetifa<sup>9</sup>, Richard Njoum<sup>1</sup>, Christian T Happi<sup>4,12,17+</sup> \*These authors contributed equally to this work

+ Correspondences: Christian T Happi (happic@run.edu.ng)

- 1. Virology Service, Centre Pasteur du Cameroun, 451 Rue 2005, Yaounde 2, P.O. Box 1274
- Institute of Ecology and Evolution, University of Edinburgh, The King's Buildings, Edinburgh EH9 3FL, UK.
- 3. Department of Parasitology and Entomology, Nnamdi Azikiwe University, Awka, Nigeria.
- 4. African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria
- 5. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA
- 6. The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- 7. Theiagen Genomics, Highlands Ranch, CO, USA
- 8. Department for the Control of Disease, Epidemics and Pandemics, Ministry of Public Health, Yaounde, Cameroon
- 9. Nigeria Centre for Disease Control and Prevention., Abuja, Nigeria
- 10. Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
- 11. Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia
- 12. Department of Biological Sciences, Redeemer's University, Ede, Osun State, Nigeria.
- 13. Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium
- 14. Department of Biomathematics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
- 15. Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, USA
- 16. Scripps Research Translational Institute, La Jolla, CA 92037, USA.
- 17. Department of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA 02115, USA

1 Nigeria and Cameroon reported their first mpox cases in over three decades in 2017 2 and 2018 respectively. The outbreak in Nigeria is recognised as an ongoing human epidemic. However, owing to sparse surveillance and genomic data, it is not known 3 4 whether the increase in cases in Cameroon is driven by zoonotic or sustained human transmission. Notably, the frequency of zoonotic transmission remains 5 unknown in both Cameroon and Nigeria. To address these uncertainties, we 6 investigated the zoonotic transmission dynamics of the mpox virus (MPXV) in 7 Cameroon and Nigeria, with a particular focus on the border regions. We show that 8 9 in these regions mpox cases are still driven by zoonotic transmission of a newly identified Clade IIb.1. We identify two distinct zoonotic lineages that circulate 10 11 across the Nigeria-Cameroon border, with evidence of recent and historic cross border dissemination. Our findings support that the complex cross-border forest 12 ecosystems likely hosts shared animal populations that drive cross-border viral 13 spread, which is likely where extant Clade IIb originated. We identify that the 14 closest zoonotic outgroup to the human epidemic circulated in southern Nigeria in 15 October 2013. We also show that the zoonotic precursor lineage circulated in an 16 17 animal population in southern Nigeria for more than 45 years. This supports findings that southern Nigeria was the origin of the human epidemic. Our study 18 19 highlights the ongoing MPXV zoonotic transmission in Cameroon and Nigeria, 20 21 underscoring the continuous risk of MPXV (re)emergence.

22 Mpox is a viral zoonosis resulting from infection with the Orthopoxvirus mpox virus 23 (MPXV) that is endemic in as-yet-unknown animal reservoirs in West and Central 24 Africa.<sup>1,2</sup> Since MPXV was first characterized in humans in the Democratic Republic of the Congo (DRC) in 1970, there have been limited outbreaks and sporadic cases in rural 25 regions of endemic countries.<sup>3–5</sup> However, since 2016, there have been a marked 26 27 increase in mpox cases in endemic as well as non-endemic countries in Africa.<sup>2</sup> It is unclear whether the increase in cases across the region is driven by increased zoonotic 28 infections, or whether MPXV may have cryptically emerged to sustained transmission in 29 30 the human population.<sup>6,7</sup> Notably, Nigeria and Cameroon reported their first mpox cases in over three decades in September 2017 and May 2018 respectively.<sup>5,7–9</sup> The Nigerian 31 32 outbreak has now been recognised as an ongoing human epidemic, driven by sustained transmission after emergence in the human population around 2014.<sup>10–12</sup> MPXV has two 33 major clades: Clade 1, which is endemic to non-human animals in Central Africa, and 34

Clade II with subclades Clade IIa and Clade IIb, which are endemic in Nigeria and the wider West Africa.<sup>1,13</sup> The Clade IIb sequences representing the sustained human-tohuman transmission in Nigeria from 2017 onwards are referred to as hMPXV-1.<sup>10,11,14</sup>

38

39 Contrastingly, Cameroon's recent increased incidence was driven by sporadic cases and 40 limited outbreaks resulting from zoonotic transmission.<sup>7</sup> Recent work has shown that zoonotic cases in Cameroon are driven by Clade I and Clade IIb.<sup>7</sup> The clade distribution 41 42 in Cameroon is structured by the biogeographic barrier of the Sanaga river as well as 43 segregated forest systems, including the Congo Basin Forests, the Cameroonian Highlands Forests, and the Lower Guinean Forests.<sup>7</sup> The Nigeria-Cameroon border is 44 45 covered by the contiguous Cameroonian Highlands forest belt that extends into both countries. These forest ecosystems provide suitable ecological conditions to host animal 46 reservoirs that may move across borders.<sup>15,16</sup> In these regions, agricultural activities, 47 48 subsistence hunting, the consumption of wild game and human settlements in forested areas owing to internal displacement heightens exposure at the human-animal interface 49 as well as the associated risk of zoonotic transmission.<sup>7,9</sup> There is also a high level of 50 51 human movement across the long and porous Nigeria-Cameroon border. This can potentially drive bidirectional transmission across the border, especially as the human 52 epidemic in Nigeria and incidence in Cameroon continues to grow.<sup>9,12</sup> 53

54

However, the transmission dynamics of MPXV across the Nigeria-Cameroon border remains obscured with limited sampling. With sparse genomic data from the region, the frequency of continued zoonotic transmission and the associated risk of re-emergence in Nigeria and Cameroon remains unknown.<sup>12</sup> It is unclear whether the increased number 59 of cases in Cameroon were introductions from the ongoing human epidemic in Nigeria, if they were driven by zoonotic spillover events, or cryptic sustained human-to-human 60 transmission as observed in Nigeria.<sup>7,9</sup> It is vital to improve our understanding of the 61 62 transmission dynamics across the border to better understand the risk of bidirectional transmission and recurrent spillover events in both countries. Enhanced genomic 63 64 surveillance of MPXV in Cameroon and Nigeria, particularly from the forested border regions, could provide insight into these questions. To address this, we generated new 65 genomic data to investigate the zoonotic transmission dynamics of MPXV in Cameroon 66 67 and Nigeria as part of a Pan-African consortium formed to collate the largest MPXV dataset from Africa to date.<sup>12</sup> 68

69

73

70 **Results** 

# Ongoing mpox cases in Cameroon are driven by zoonotic transmission of newly identified Clade IIb.1

In 2022, Cameroon saw a large increase in mpox cases.<sup>7</sup> It is unclear whether the 74 75 reported increase was driven by enhanced surveillance attributable to the global B.1 outbreak, or to increased zoonotic transmission or cryptic sustained human-to-human 76 transmission as observed in Nigeria.<sup>7</sup> Towards understanding this, we generated 10 new 77 78 sequences from samples collected from 2018 to 2022 in Cameroon. All 10 of our sequences were identified as Clade IIb. The majority of our Cameroonian sequences 79 80 were sampled from the rural South-West and North-West regions that border Nigeria (Figure 1A). The South-West and North-West regions account for the second and third 81 highest number of mpox cases in Cameroon after the Centre region, where Clade I 82 predominantly circulates.<sup>7</sup> We also included four Clade IIb genomes sampled from 83

Nigeria from 2022 to 2023 as part of a complementary study from our consortium (Figure
1A).<sup>12</sup> Our four Nigerian sequences were sampled from states that border Cameroon,
namely Abia and Akwa Ibom (Figure 1A).

87

To understand the relationship of our sequences to the human epidemic in Nigeria, we reconstructed the Clade IIb phylogeny (Figure 1B). We found that all ten Cameroonian sequences form a divergent basal sister lineage to hMPXV-1 and its zoonotic outgroup, the oldest zoonotic sequence sampled in Nigeria in 1971 (KJ642617) (Figure 1B). We term this divergent zoonotic lineage Clade IIb.1, and lineage encompassing zoonotic outgroup KJ642617 and hMPXV-1 as Clade IIb.2 (Figure 1B).

94

95 To investigate whether the sampled cases in Cameroon were a result of sustained human-to-human transmission or zoonotic infection, we investigated the APOBEC3 96 mutational bias characteristic of sustained human transmission in our sequences.<sup>10,17,18</sup> 97 98 We reconstructed all single nucleotide polymorphisms (SNPs) across our Clade IIb 99 phylogeny. We mapped mutations to their applicable branches, and quantified the 100 proportion of APOBEC3 mutations (C $\rightarrow$ T or G $\rightarrow$ A in the correct dimer context) across the 101 branches of Clade IIb (Figure 1B, C). We found that only 7 of the 124 SNPs (5.7%) on 102 the internal branches of Clade IIb excluding hMPXV-1 were consistent with APOBEC3 103 editing (Figure 1C). This strongly suggests that all of the Clade IIb.1 cases sampled in 104 Cameroon are the result of zoonotic transmission (Figure 1C). Taken together, it suggests 105 that ongoing cases in Cameroon are driven by continued zoonotic events by the newly

identified Clade IIb.1, not sustained human-to-human transmission as observed in
 Nigeria.<sup>7,10,12</sup>

108

However, we did find likely cases of secondary human transmission in Cameroon. Two 109 110 cases (22V-08501 and 22V-08503) represented a likely household transmission between 111 a parent and their child from the Bangem health district in the South-West region (Figure 1A. B). The parent reported contact with and consumption of wild game meat. These two 112 113 sequences are most closely related to 18V-04552, which represents the first confirmed case in the 2018 outbreak from Niikwa in the North-West region.<sup>9</sup> The patient had no 114 115 reported contact with wild animals or an mpox-like case, and no travel history to Nigeria. 116 There were another two sequences that were identical after masking the alignment (see 117 Methods), but with uncertain epidemiological linkage. One was a driver (22V-07911) who 118 reported symptom onset in the South-West locality of Tombel, but sought care in the 119 Littoral region (Figure 1A). The patient reported no other travel history, no contact with 120 symptomatic mpox cases, and no contact with wild animals. The second case was an 121 infant in Nkwen, North-West Region (22V-09327), who had been infected through intra-122 familial transmission from their sibling (not sampled). There were two other cases that were respectively separated by one and two SNPs from the driver and infant. The first 123 124 (22V-09403) was the nurse at a hospital in the North-West region who cared for the infant 125 (22V-09327). The second (22V-07968) case was a community health worker in Tombel 126 in the South-West, who reported contact with a bike-rider presenting Mpox-like rashes. The two cases from Tombel had no confirmed contact. 127



128

129 Figure 1: A) Map of Nigeria and Cameroon showcasing the ecological setting of zoonotic MPXV in Nigeria and 130 Cameroon. The forest cover, including the discontiguous cross-border forest belt referenced in the text, are highlighted 131 in green. The border between Nigeria and Cameroon is annotated in deep red, with the Rivers Niger in Nigeria and 132 Sanaga in Cameroon highlighted in light blue. Our sampling sites across the border are annotated in orange and blue 133 respectively for Cameroon and Nigeria, and states of interest annotated with highlighted borders. B) Reconstructed 134 SNPs mapped onto the branches of the Clade IIb phylogeny. APOBEC3 mutations are annotated in yellow and red, 135 with non-APOBEC3 mutations in gray and black. The novel lineage sampled from Cameroon and Akwa Ibom in Nigeria 136 137 named Clade IIb.1, is highlighted in the gray box and annotated. Our new zoonotic outgroup from Abia is annotated as "Zx", and forms part of Clade IIb.2 which is annotated in the darker blue box. Lineage A, representing the sustained human epidemic in Nigeria, is highlighted in the light blue box as hMPXV-1. C) The number of APOBEC3 SNPs out of 138 139 140 all mutations for the novel zoonotic lineage Clade IIb.1, the hMPXV-1 subtree (highlighted and annotated in Figure B) and the Zoonotic subtree of Clade IIb.2 (KJ642617 and Zx annotated in Figure B). 141

# 142 Clade IIb zoonotic lineages circulate across the143 Nigeria-Cameroon border

The Nigeria-Cameroon border is covered by a complex forest belt extending into both countries that hosts many animal populations susceptible to MPXV infection (Figure 1A).<sup>15,16</sup> There is also a lot of trans-border human movement, potentially driving viral spread between the two countries.<sup>9</sup> To better understand viral spread across the Nigeria-Cameroon border, including from animal populations that may freely move across border i.e. a shared host reservoir, we particularly included four sequences from Abia and Akwa lbom in southern Nigeria that was not part of the ongoing hMPXV-1 epidemic in Nigeria.<sup>12</sup>

All save one of our Cameroonian sequences were sampled from the rural areas in theNorth-West and South-West regions that border southern Nigeria (Figure 1A).

153

154 In our phylogeny, we found that the two sequences from Akwa Ibom in southern Nigeria 155 cluster in the newly identified Clade IIb.1 with the sequences from Cameroon (Figure 1B). The sequences from Akwa Ibom showed no evidence of APOBEC3 editing, indicating 156 157 they were a result of zoonotic infection as well (Figure 1 B, C).<sup>10,11</sup> They represented 158 independent spillover events from a shared animal population, as the sequences were 159 separated by 10 SNPs and the cases were reported from different local government areas 160 (Figure 1B). The Akwa Ibom sequences were most closely related to a sequence (22V-161 07739) we sampled in Mbongue in the South-West region of Cameroon (Figure 1A). Akwa 162 Ibom is a state in southern Nigeria adjacent to Cross River state, which shares a forested 163 border with the regions in Cameroon from where our cases were sampled (Figure 1A). 164 The two Akwa Ibom sequences and the one from Mbongue were very divergent from one 165 another, separated by 25 and 29 SNPs respectively. The sequence 22V-07739 was 166 sampled from a farmer who reported contact with only bats, with no history of travel or 167 exposure to mpox cases in the community. Taken together, this supports that in both Nigeria and Cameroon Clade IIb.1 predominantly represents independent zoonotic 168 169 transmissions from a diverse viral population that has diverged over time in a shared 170 animal reservoir in the the cross-border forest ecosystems of southern Nigeria and 171 Western Cameroon.

172

The single Clade IIb.1 sequence (21V-04877) we sampled from the Centre region ofCameroon, which is normally predominated by Clade I, was from an internally displaced

person (IDP). Epidemiological data confirms that the IDP was from the North-West, and
was likely infected in the Littoral region where the patient was residing at time of disease
onset before being referred to a health facility in the Centre region.

178

179 In light of the high divergence observed between Clade IIb.1 and Clade IIb.2 (Figure 1B), 180 we next investigated how long Clade IIb has been circulating in the cross-border animal 181 population. We performed Bayesian phylogenetic reconstructions under the two-epoch 182 model of O'Toole et al. implemented in BEAST, combining our sequences with the dataset we produced from the Nigerian epidemic.<sup>10,12</sup> We found that Clade IIb.1 diverged 183 184 from Clade IIb.2 around six decades ago in the animal reservoir (Figure 2). The common 185 ancestor of Clade IIb.1 and Clade IIb.2 circulated in January 1966 (median time to the most recent common ancestor or tMRCA, 95% HPD October 1962 to December 1968). 186 187 There is also evidence of more recent cross-border viral spread in Clade IIb.1, as the 188 Akwa Ibom sequences diverged from the Mbongue sequence in March of 2009 (tMRCA. 189 95% HPD November 2004 to August 2013). Sparse sampling limits our ability to 190 definitively resolve the geographic origin of the common ancestor of all of Clade IIb 191 (Figure 2). However, the country of origin and direction of spread is less meaningful for a 192 virus in an animal population in a cross-border ecosystem. Taken together, our Clade IIb 193 sequences support both recent and historic viral spread across a porous Nigeria-194 Cameroon border, likely originating in a shared animal population hosting significant 195 diversity in the cross-border forest ecosystem.



196

Figure 2: The time-resolved phylogeny of Clade IIb. hMPXV-1, representing the human epidemic in Nigeria, is collapsed. Our new zoonotic outgroup from Abia is annotated as "Zx", with Clade IIb.2 annotated in the dark blue box. Clade IIb.1 is annotated in text. Distributions on the x-axis represent the tMRCA of the color matching node.

# Zoonotic ancestor of hMPXV-1 circulated in southern Nigeria in late 2013

203 Before this study, the closest zoonotic outgroup to hMPXV-1 (KJ642617) was sampled in

204 1971 in Abia province in southern Nigeria (Figure 1A, 2A). This suggests that the

205 precursor lineage of hMPXV-1 may have circulated in the animal population in the cross-

206 border forest belt in the south. To determine whether we've sampled a closer zoonotic

207 outgroup to hMPXV-1 from this precursor lineage, we investigated the relationship of our

208 four zoonotic sequences from Nigeria to hMPXV-1.

- 209
- 210 In our Clade IIb phylogeny, we found that two sequences of our sequences from Abia in
- southern Nigeria formed a more recent Clade IIb.2 outgroup to hMPXV-1 than KJ642617
- 212 ("Zx" in Figure 1B).<sup>12</sup> There was no evidence of APOBEC3 mutational bias in the Abia

medRxiv preprint doi: https://doi.org/10.1101/2024.06.18.24309115; this version posted June 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

213 sequences, indicating they represented zoonotic infections (Figure 1 B,C). We refer to 214 our new outgroup sequences as the zoonotic outgroup hereafter ("Zx" in Figure 1-2). As the zoonotic outgroup shares a common ancestor with hMPXV-1, they represent the 215 216 closest sequences to the zoonotic precursor of hMPXV-1 (Figure 1B). The zoonotic 217 outgroup breaks up the long stem branch from the common ancestor of KJ642617 and 218 hMPXV-1, reducing it from 27 to 8 SNPs (Figure 1B). The two sequences are separated 219 by 8 non-APOBEC3 SNPs, signifying they represent independent zoonotic transmissions 220 (Figure 1B). The zoonotic Clade IIb.2 from Abia, including the new outgroup and 221 KJ642617, is phylogenetically distinct from Clade IIb.1 circulating in Akwa Ibom and 222 Cameroon. This indicates that we've sampled two distinct zoonotic lineages in the regions 223 in proximity to the Nigeria-Cameroon border (Figure 1A, B). Notably, Abia is a neighboring 224 state to Akwa Ibom and Cross River state, which borders Cameroon and shares the 225 contiguous forest belt that likely hosts the shared animal population that drove the cross-226 border dissemination of Clade IIb.1 (Figure 1A).

227

228 The recent divergence between our new zoonotic outgroup and hMPXV-1 places a tight 229 bound on when the zoonotic ancestor of hMPXV-1 was circulating in an animal population 230 in the region. In our Bayesian phylogenetic reconstructions, we estimated that the 231 outgroup shared a common ancestor with hMPXV-1 that circulated in November 2013 232 (95% HPD April 2012 - April 2015) (Figure 2). In a complementary study, we used the 233 additional phylogenetic information of the outgroup to estimate that hMPXV-1 initially 234 emerged in humans July 2014 (95% HPD 6 October 2013 - 23 February 2015).<sup>12</sup> This 235 suggests that the ancestor of hMPXV-1 circulated in animals in Abia or southern Nigeria 236 for less than a year before emergence, though credible intervals overlap. This is

consistent with our complimentary work that found that hMPXV-1 most likely originated in
Rivers State in Nigeria, which borders Abia.<sup>12</sup> It is also consistent with the epidemiological
data, which shows that the southern states were the epicenter of the early stages of the
Nigerian mpox epidemic.<sup>12</sup>

241

Both the new zoonotic outgroup and KJ642617 (sampled in 1971) from Clade IIb.2 were sampled in Abia state. This suggests that the zoonotic lineage from which hMPXV-1 descended may have persistently circulated in the animal reservoir in southern Nigeria for decades. In our Bayesian phylogenetic analysis, we found that the Zx zoonotic outgroup diverged from the older zoonotic KJ642617 around March 1968 (95%HPD December 1965 - February 1970) (Figure 2). This suggests that the hMPXV-1 precursor lineage circulated in an animal population in Abia or southern Nigeria for at least 45 years.

# The zoonotic evolutionary rate is 20-50 times lower than the APOBEC3-mediated rate in humans

In our previous work under a partitioned epoch model, we found that APOBEC3 activity 251 increased the evolutionary rate of hMPXV-1 20-fold across sustained human 252 253 transmission.<sup>12</sup> To compare the evolutionary rates from the human epidemic to the rate 254 in animals, where APOBEC3-mediated evolution is absent, we estimated the rate for the 255 novel zoonotic Clade IIb.1, and the zoonotic Clade IIa combined (Figure 3A). We 256 performed model selection to compare four clock models: the strict clock, the uncorrelated 257 relaxed clock with a lognormal (UCL) and gamma (UCG) distribution respectively and the fixed local clock (FLC), allowing the two clades to evolve at different rates.<sup>19,20</sup> Model 258 259 testing showed strong positive support for a FLC over the UCG (Bayes Factor - BF - 177), 260 strict clock (BF 189) and the UCL (BF 204) (Extended Data table 1).

261

262	Under the FLC model, we estimated an evolutionary rate of 4.3×10 <sup>-6</sup> (95% HPD 3.1×10 <sup>-6</sup>
263	$-5.6 \times 10^{-6}$ ) for Clade IIa, and 2×10 <sup>-6</sup> (95% HPD 1.5×10 <sup>-6</sup> – 2.6×10 <sup>-6</sup> ) for zoonotic Clade
264	IIb (Figure 3B). The background rate estimated for Clade IIb hMPXV-1 i.e. the human
265	epidemic 4.8×10 <sup>-6</sup> (95% HPD 4.2×10 <sup>-6</sup> - 5.5×10 <sup>-6</sup> ) is consistent with our Clade IIa rate. <sup>12</sup>
266	These rates translate to 1-2 substitutions a year. However, our zoonotic Clade IIb rate is
267	slower than the background rate estimated for hMPXV-1 and the rate of Clade IIa,
268	equating to ~1 substitution every 2-3 years. The Clade IIb zoonotic rate is consistent with
269	the rate previously estimated by Patrono et al. for a Clade IIa outbreak in chimpanzees,
270	and marginally higher than the rate estimate for zoonotic Clade I.21,22 All of our non-
271	APOBEC3 rates are within the expectation of double-stranded DNA viruses, but are lower
272	than the rates estimated for smallpox. <sup>23–25</sup> The relatively lower Clade IIb zoonotic rate
273	indicates that there was no elevation in the evolutionary rate in non-human animals before
274	emergence. Most notably, the APOBEC3 rate estimated from the human epidemic (1×10-
275	$^4$ (95% HPD 8.8×10 $^5$ - 1.14×10 $^4$ ) is approximately 20-50 times higher than the
276	evolutionary rate estimated from non-human animals. <sup>12</sup> Our results were consistent
277	across all clock models (Extended Data Figure 1).



Figure 3: A) Global MPXV phylogeny of Clade I, Clade IIa and Clade IIb. Our Clade IIb sequences are annotated as
 tip points B) Comparison of the evolutionary rate of the hMPXV-1 APOBEC3, hMPXV-1 Non-APOBEC3, Zoonotic
 Clade IIa and Zoonotic Clade IIb.1 under the two-epoch partitioned model the local clock model (Clade IIa, Clade IIb.1)
 respectively.

#### 284 **Discussion**

285 The ongoing MPXV zoonotic transmission events in Cameroon and Nigeria identified in this study underscores the continuous risk of MPXV emergence and re-emergence, which 286 287 is likely still significantly underestimated owing to under-ascertainment of cases and 288 sparse genomic data. In our Cameroonian dataset, we found that all ten sampled cases 289 resulted from zoonotic infections or secondary transmission of the novel Clade IIb.1, with no evidence of sustained human-to-human transmission in Cameroon.<sup>10–12</sup> Combined 290 with our larger dataset<sup>12</sup>, we found only four of the 112 sequences from Nigeria were 291 292 zoonotic in origin, with the remainder part of the ongoing hMPXV-1 human epidemic.<sup>12</sup> 293 However, our samples only represent 4.2% and 7.5% of all suspected mpox cases in 294 Nigeria and Cameroon respectively from 2017 onwards. It is likely that enhanced 295 surveillance in the human population, especially in border-adjacent communities at the 296 animal-human interface, will reveal more zoonotic transmission events.

297

298 In this study, all of our Cameroonian sequences were sampled from individuals living in 299 rural areas in the South-West and North-West regions, whereas our sequences from 300 Nigeria were sampled in the southern states of Akwa Ibom and Abia. The North-West and 301 South-West of Cameroon is dominated by the Cameroonian Highlands and Guinean 302 Lower forest ecosystems, which extends into southern Nigeria.<sup>15</sup> These cross-border forest ecosystems are areas of high biodiversity, hosting a wide range of potential hosts 303 304 susceptible to MPXV. The precise animal reservoir for MPXV currently remains unknown. 305 However, various small mammals, primarily squirrel and other rodent species, have shown serological or viral evidence of infection.<sup>13,26–30</sup> It is likely that a diverse group of 306 307 squirrel and rodent species maintain the reservoir, while non-human primates and other species act as intermediate hosts.<sup>31</sup> Our findings support that the cross-border forest 308 309 ecosystems likely hosts the shared reservoir driving cross-border viral dispersal, where 310 Clade IIb likely originated. In light of this, we need improved surveillance in the wildlife 311 population in the forest systems along the Nigeria-Cameroon border to better understand 312 the transmission and maintenance of MPXV in animal hosts. Additional sampling is likely 313 to reveal significant unsampled viral diversity in the reservoir, as observed in the deep 314 divergences just in the sampled tree.

315

The factors that drove hMPXV-1's recent emergence in the human population are still unclear. Previous studies have established that hMPXV-1 resulted from a single zoonotic event.<sup>10,12</sup> Most spillover events result in sporadic human cases or stuttering transmission chains that largely go unobserved without establishing substantial human-to-human transmission.<sup>32,33</sup> It remains unclear why this zoonotic event successfully established

321 sustained transmission. There are a few factors that may have contributed to MPXV's322 recent emergence.

323

324 Declining herd immunity from smallpox vaccination

325 Vaccination against fellow Orthopoxvirus smallpox offers some degree of cross-326 protection against MPXV.<sup>34,35</sup> In Africa, large scale smallpox vaccination campaigns stopped in the early 1980s after global eradication in 1977.<sup>36</sup> As a result, herd immunity 327 328 has significantly declined over recent decades and the population of susceptibles have 329 concurrently increased. This is particularly relevant to African countries, where the median age is below 18 years.<sup>37</sup> A lack of protective immunity not only increases the 330 331 chances of a successful zoonotic infection, but also increases the probability of onward transmission after the initial zoonotic event.35,36 332

333

334 Increased exposure at the animal-human interface

Humans are exposed to potentially infected MPXV hosts at the human-animal interface 335 336 through various activities, with exposure increasing in recent years. Crucially, wild game 337 consumption is common for subsistence in many regions of Africa, with many of the commonly targeted mammalian species susceptible to MPXV infection.<sup>13,38,39</sup> The rising 338 demand for wild game meat, along with population growth, socioeconomic conditions, 339 340 and internal displacement has led to greater exposure through increased hunting, 341 consumption, and trade.<sup>36,40</sup> Notably, the Nigeria-Cameroon forest belt hosts a substantial 342 amount of hunting and wild game trade due to its rich species abundance and diversity.<sup>41</sup> 343 Trade of shared animal sources or shared markets may facilitate cross-border transmission.<sup>42,43</sup> The North-West and South-West of Cameroon have been severely 344

345 affected by conflict since 2017, resulting in large-scale internal displacement and increased movements to the neighboring countries including Nigeria.<sup>7</sup> This large-scale 346 347 and undocumented trans-border human movement may drive viral introductions to new 348 populations. Many IDPs have been forced to settle in forested areas to escape conflict, resulting in increased exposure for an already vulnerable community.<sup>44</sup> Two of our 349 350 sampled cases were IDPs, including the farmer who reported leaving the South-West five 351 years ago. The patient reported that approximately 10 000 other people left their villages and homes due to the social unrest to live in the same settlement area in the bush. 352 353 Additionally, ecosystems have been disrupted by land use intensification, including 354 deforestation, expanding agriculture and urbanization.<sup>7,15,36,45</sup>

355

#### 356 Initial zoonotic transmission in a mobile, connected subpopulation

357 Heterogeneities in the basic reproductive number, particularly superspreading dynamics, 358 are strong determinants of emergence and early epidemic spread.<sup>46</sup> MPXV's emergence 359 and successful onward transmission was most likely driven by an initial zoonotic 360 transmission within a connected, mobile subpopulation, where subsequent transmission 361 was more probable owing to behavioral and demographic factors driving rapid 362 dissemination.<sup>47,48</sup> Our previous work supports that hMPXV-1 still only circulates in a restricted subpopulation in Nigeria.<sup>12</sup> Our previous findings also strongly suggest that 363 364 these early events occurred in a subpopulation in southern Nigeria.<sup>12</sup>

365

366 Viral adaptation in the natural reservoir or in humans following zoonotic transmission

367 We think it's unlikely that adaptation in the natural reservoir drove emergence. The two

368 non-synonymous non-APOBEC3 substitutions along the stembranch to hMPXV-1 from

369 our close zoonotic outgroup are both relatively conservative. However, it is not possible 370 to infer that any of the stem or deeper branch substitutions in the tree did not confer an 371 advantage for human infection and transmission without experimental characterization. It 372 is also possible that MPXV's emergence was facilitated by adaptation in the human 373 population after the initial zoonotic transmission. However, prior work showed that the set of nucleotide and amino acid substitutions accessible by APOBEC3 activity is restricted.<sup>10</sup> 374 375 This may constrain viral adaptation, as substitution options at non-deleterious target sites 376 become saturated over time. However, adaptation is more probable across extended chains of transmission, driven by founder effects and selection.<sup>10,49</sup> Potentially adaptive 377 378 changes have been observed in later descendants of the hMPXV-1 Lineage A, including disruption of immunomodulatory genes.<sup>11,12</sup> However, these changes occurred after 379 380 prolonged circulation in the human population. We have estimated that MPXV circulated cryptically in the human population in Nigeria for approximately three years before 381 detection.<sup>12</sup> Nonetheless, we find it unlikely that any of the early substitutions in the 382 383 human epidemic facilitated sustained transmission. Of the earliest six APOBEC3 384 mutations that occurred in the human population, only two are non-synonymous. Without 385 experimental characterization, we cannot conclude that any of the early substitutions did 386 not confer an adaptive advantage that facilitated transmission after the initial zoonotic transmission. However, we consider this scenario improbable. 387

388

#### 389 **Methods**

#### 390 Ethics declaration

No ethical approval was required for this study as it is based on collecting data from 391 Cameroon's national surveillance program, for which Centre Pasteur du Cameroun (CPC) 392 393 is the National Reference Laboratory (NRL). The surveillance program includes genomic 394 surveillance as provided in this study to inform public health preparedness. Under the 395 program, Individual written or oral informed consent was obtained from all mpox 396 suspected cases after detailed information and explanations of the sampling purpose 397 were provided. Informed consent for children was obtained from their parents or 398 recognized guardians. All samples from Nigeria were similarly collected during national 399 outbreak surveillance by the Nigerian CDC. Under the surveillance program, individual 400 written or oral informed consent was obtained as detailed above.

#### 401 **Sampling**

402 From 2018 to 2022, a total of 28 human mpox cases were identified by the national 403 surveillance program in Cameroon. Suspected cases were identified by community health 404 workers (CHWs) or clinicians and samples collected by a Rapid Response and 405 Investigation Team (RRIT) equipped with appropriate personal protective equipment 406 (PPE) under the guidance of Regional Centers for Epidemic Prevention and Control 407 (CERPLE) and following the national guidelines for surveillance and response to mpox 408 outlined by the the Department for the Control of Disease, Epidemics and Pandemics (DLMEP) of the Cameroonian MoH. Cases were confirmed by standard and genotyping 409 real-time PCR at the CPC which host the NRL for mpox in Cameroon.<sup>7</sup> From the total 410

411 cases, we selected ten for sequencing based on Clade genotyping by rtPCR, cycle 412 threshold (value < 30) and sample availability. Samples were screened for DNA 413 concentration and guality (total DNA >500 ng and absorbance ratio >1.8 260/230 and 414 260/280). Samples represented maculopapular vesicles, skin crust or blood samples. The four Nigerian sequences are from a complementary study.<sup>12</sup> For this dataset, 415 416 samples were collected by laboratory personnel and Local Government Area (LGA) 417 Disease Surveillance and Notification Officers (DSNOs) equipped with appropriate 418 personal protective equipment (PPE), adhering to the guidelines outlined in the Nigeria 419 Centre for Disease Control and Prevention (NCDC) National Monkeypox Public Health Response Guidelines.<sup>50</sup> Samples from both sites comprised: swabs from the exudate of 420 421 vesicular or pustular lesions, lesion crusts obtained during the acute rash phase, whole 422 blood collected in ethylenediaminetetraacetic acid (EDTA) or plain/non-anticoagulated 423 tubes. All samples were labeled with case information and stored at 2-8°C during transport to either the NCDC NRL (Gaduwa-Abuja) or the Central Public Health 424 425 Laboratory (Yaba-Lagos) for Nigeria, and the NRL at CPC in Cameroon (Yaounde). On 426 arrival, the crusts and swabs were eluted, while the serum/plasma was separated from 427 the red cells. Subsequently, these components were stored at ultralow temperatures of ≤-70°C at the NCDC and CPC biorepositories. 428

#### 429 Sequencing

Enrichment bead-linked transposomes were used to tagment the extracted DNA and enriched using the Illumina- rna -prep enrichment with the VSP panel. Libraries were quantified using dsDNA BR Assay, normalized to a concentration of 0.6nM and sequenced on the Illumina NovaSeq 6000 platform with a read length of 151 base pair

paired end at the African Centre of Excellence for Genomics of Infectious Diseases
(ACEGID), based at Redeemer's University, Ede, Nigeria.

#### 436 **Genome assembly**

We performed the initial assembly *de novo* with the viral-ngs pipeline. We subsequently performed reference based assembly with an in-house pipeline.<sup>51</sup> We mapped reads against a Clade IIb reference genome (NC\_063383) with *bwa-mem*<sup>52</sup>, and called consensus using samtools<sup>53</sup> and iVar.<sup>54</sup>

#### 441 Genomic dataset curation

We combined our 10 sequences from Cameroon with four zoonotic sequences from Nigeria identified as part of a larger study.<sup>12</sup> We combined these 14 sequences with our sequences reported elsewhere, and all available Clade IIb MPXV genomes of high quality from Genbank.<sup>12</sup> We included a single sequence representing the global B.1 outbreak, as it was not our focus. In total, our dataset consists of 202 sequences.

#### 447 Phylogenetic Analysis

448 We used the 'squirrel' package (https://github.com/aineniamh/squirrel) developed by 449 O'Toole et al. (2022) to align our sequences to the Clade IIb reference genome 450 (NC 063383), which represents an early hMPXV-1 sequence. We trimmed the alignment, 451 and masked repeat regions or regions of low complexity. We reconstructed the Clade IIb phylogeny with IQ-TREE v2.0, under the Jukes-Cantor substitution model.<sup>55</sup> We rooted 452 453 the tree to KJ642615, a zoonotic sequence sampled in Nigeria in 1978, as it is notably 454 divergent from the remaining Clade IIb diversity and collapsed all zero branch lengths. 455 We performed ancestral state reconstruction across the Clade IIb phylogeny with IQ-TREE2.<sup>55</sup> We mapped all of the nucleotide mutations that occurred unambiguously 456

457 across the phylogeny to internal branches. Additionally, we cataloged the dimer genomic 458 context of all C $\rightarrow$ T or G $\rightarrow$ A mutation, as described by O'Toole *et al.*<sup>8</sup> We classified our 459 sequences into lineages under the nomenclature developed in Happi *et al.*<sup>14</sup> using 460 Nextclade.<sup>56</sup>

#### 461 Modeling APOBEC3-mediated evolution

We adopted a similar approach to the Bayesian phylogenetic analyses as described in 462 O'Toole et al.<sup>10</sup> using the BEAST 1.10<sup>57</sup> platform powered through the BEAGLE high-463 performance computing library.<sup>58</sup> Briefly, we partitioned the Clade IIb alignment into two 464 465 partitions representing 1) sites with potential APOBEC3 modifications (specifically C→T 466 and  $G \rightarrow A$  substitutions in the dimer context TC and GA) together with fully conserved C and G target sites, with all other sites masked, and 2) sites with the APOBEC3 target sites 467 468 masked inversely. The APOBEC3 partition was 24 680 unmasked sites, whereas the non-469 APOBEC3 partition was 172 529 sites. We used the GTR+G substitution model with four 470 rate categories for the non-APOBEC partition. For the APOBEC partition, we used a substitution model where the nucleotides are characterized as modified (T) and 471 unmodified (C). We use a two-state continuous-time Markov chain with an asymmetric 472 473 rate to permit  $C \rightarrow T$  mutations but not the reverse.

474

In the two-epoch mode, we allow the evolutionary rate to shift from the background rate (driven by the polymerase error rate) to the APOBEC3 rate at a specific time point for the APOBEC3 partition. We incorporated a local clock to scale the mutation proportion attributed to APOBEC3 activity across the branches up to the transition time. We allowed the non-APOBEC3 partition to evolve under the background evolutionary rate across the entire phylogeny.<sup>12</sup> We used a two-phase coalescent model, where the tree from the 481 MRCA of hMPXV-1 onward was modeled with an exponential growth model, and the 482 earlier phase was modeled as a constant-population size coalescent model. For each 483 model, we ran two independent chains of 100 million states to ensure convergence, 484 discarding the initial 10% of each chain as burn-in. The chains were then combined with 485 LogCombiner. For all subsequent analyses, we assessed convergence using Tracer, and 486 constructed a maximum clade credibility (MCC) tree in TreeAnnotator 1.10.<sup>59</sup>

## 487 Estimating the evolutionary rate of Clade IIa and Clade 488 Ilb zoonotic sequences

We estimated the evolutionary rates of the zoonotic Clade IIa and Clade IIb using the 489 BEAST 1.10 software.<sup>57</sup> We modeled the substitution process under a GTR+G model.<sup>60</sup> 490 491 We employed three different models: the strict clock; a fixed local clock that constrained 492 Clade IIa and Clade IIb into respective monophyletic clades with different evolutionary rates: the uncorrelated relaxed clock with a lognormal distribution (UCL).<sup>19,61,62</sup> For each 493 494 of the models we employed both the noninformative continuous time markov chain 495 (CTMC) prior on the overall rate scalar which is a default in BEAST1.10.5 and then used an overall rate 10<sup>-6</sup> for pox viruses <sup>20, 22, 23</sup> with gamma distribution that imposes a stronger 496 penalty for the rates than the default prior.<sup>63</sup> Both prior produced similar results. We ran 497 498 two independent MCMC chains of 50 million states, sampling every 1000 states and 499 combining post burn-in samples (10% burn-in). We assessed convergence using Tracer, ensuring that all effective sample sizes were above 200.59 To perform model selection, 500 501 we inferred the log marginal likelihood using the generalized stepping-stone sampling 502 (GSS).<sup>64,65</sup> We excluded the KJ642615 sequence sampled in 1978 from Nigeria as it is

- significantly divergent from the remaining Clade IIb. We only included one sequence of
- the four sequences from the 2018 Chimpanzee outbreak in Cote d'Ivoire.<sup>20, 22, 24</sup>

#### 505 Geographic data

- 506 All shapes files were obtained from the FAO geoNetwork (https://www.fao.org/land-
- 507 water/databases-and-software/geonetwork/en/)

#### 508 Data availability

- 509 All sequences are available on Genbank under Accession numbers PP860025-
- 510 PP860033. All other data are available at https://github.com/andersen-
- 511 lab/MPXV\_zoonotic\_transmission\_West\_Africa, or upon request.

#### 512 Code availability

- 513 All code to run the analyses is available in <u>https://github.com/andersen-</u>
- 514 lab/MPXV zoonotic transmission West Africa

515

516

### 517 **References**

- 518 1. Nakazawa, Y. *et al.* A phylogeographic investigation of African monkeypox. *Viruses* **7**, 2168–2184
- 519 (2015).
- 520 2. Durski, K. N. et al. Emergence of monkeypox in West Africa and Central Africa, 1970-
- 521 2017/Emergence de l'orthopoxvirose simienne en Afrique de l'Ouest et en Afrique centrale, 1970-
- 522 2017. Weekly Epidemiological Record **93**, 125–133 (2018).
- 523 3. Breman, J. G. et al. Human monkeypox, 1970-79. Bull. World Health Organ. 58, 165–182 (1980).
- 524 4. McCollum, A. M. & Damon, I. K. Human monkeypox. *Clin. Infect. Dis.* 58, 260–267 (2014).
- 525 5. Yinka-Ogunleye, A. *et al.* Reemergence of Human Monkeypox in Nigeria, 2017. *Emerg. Infect. Dis.* 24, 1149–1151 (2018).
- 527 6. World Health Organization. Mpox (monkeypox)-Democratic Republic of the Congo. 2023-11528 23)[2023-12-18]. https://www. who. int.
- 529 7. Djuicy, D. D. et al. Concurrent Clade I and Clade II Monkeypox Virus Circulation, Cameroon, 1979-
- 530 2022. Emerg. Infect. Dis. **30**, (2024).
- 531 8. Yinka-Ogunleye, A. et al. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and
- epidemiological report. *Lancet Infect. Dis.* **19**, 872–879 (2019).
- 533 9. Sadeuh-Mba, S. A. *et al.* Monkeypox virus phylogenetic similarities between a human case detected
  in Cameroon in 2018 and the 2017-2018 outbreak in Nigeria. *Infect. Genet. Evol.* 69, 8–11 (2019).
- 535 10. O'Toole, Á. *et al.* APOBEC3 deaminase editing in mpox virus as evidence for sustained human
  536 transmission since at least 2016. *Science* 382, 595–600 (2023).
- 537 11. Ndodo, N. *et al.* Distinct monkeypox virus lineages co-circulating in humans before 2022. *Nat. Med.*538 **29**, 2317–2324 (2023).
- 539 12. Parker, E et al. Genomic Epidemiology Uncovers the Timing and Origin of the Emergence of Mpox in
  540 Humans. doi:10.5281/zenodo.11652886.
- 13. Doty, J. B. *et al.* Assessing Monkeypox Virus Prevalence in Small Mammals at the Human–Animal
- 542 Interface in the Democratic Republic of the Congo. *Viruses* **9**, 283 (2017).

- 543 14. Happi, C. et al. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for
- 544 monkeypox virus. *PLoS Biol.* **20**, e3001769 (2022).
- 545 15. Molua, E.L. and Lambi, C.M. Climate, Hydrology and Water Resources in Cameroon. *Environmental*546 *Issues: Problems and Prospects, Bamenda: Unique Printers, 45-66.* (2001).
- 16. Reynolds, M. G., Doty, J. B., McCollum, A. M., Olson, V. A. & Nakazawa, Y. Monkeypox re-emergence
- in Africa: a call to expand the concept and practice of One Health. *Expert Rev. Anti. Infect. Ther.* 17,
  129–139 (2019).
- 17. Isidro, J. *et al.* Phylogenomic characterization and signs of microevolution in the 2022 multi-country
  outbreak of monkeypox virus. *Nat. Med.* 28, 1569–1572 (2022).
- 552 18. Gigante, C. M. *et al.* Multiple lineages of monkeypox virus detected in the United States, 2021-2022.
  553 Science **378**, 560–565 (2022).
- 554 19. Drummond, A. J., Ho, S. Y. W., Phillips, M. J. & Rambaut, A. Relaxed phylogenetics and dating with
  555 confidence. *PLoS Biol.* 4, e88 (2006).
- 556 20. Sinsheimer, J. S., Lake, J. A. & Little, R. J. Bayesian hypothesis testing of four-taxon topologies using
  557 molecular sequence data. *Biometrics* 52, 193–210 (1996).
- 558 21. Patrono, L. V. *et al.* Monkeypox virus emergence in wild chimpanzees reveals distinct clinical
  559 outcomes and viral diversity. *Nat Microbiol* 5, 955–965 (2020).
- 560 22. Berthet, N. *et al.* Genomic history of human monkey pox infections in the Central African Republic
  561 between 2001 and 2018. *Sci. Rep.* **11**, 13085 (2021).
- 562 23. Duggan, A. T. *et al.* 17th Century Variola Virus Reveals the Recent History of Smallpox. *Curr. Biol.* 26,
  563 3407–3412 (2016).
- 24. Porter, A. F., Duggan, A. T., Poinar, H. N. & Holmes, E. C. Comment: Characterization of Two Historic
  Smallpox Specimens from a Czech Museum. *Viruses* vol. 9 (2017).
- 566 25. Duffy, S., Shackelton, L. A. & Holmes, E. C. Rates of evolutionary change in viruses: patterns and
  567 determinants. *Nat. Rev. Genet.* 9, 267–276 (2008).
- 568 26. Khodakevich, L., Jezek, Z. & Kinzanzka, K. Isolation of monkeypox virus from wild squirrel infected in
- 569 nature. *Lancet* **1**, 98–99 (1986).
- 570 27. Radonić, A. et al. Fatal monkeypox in wild-living sooty mangabey, Côte d'Ivoire, 2012. Emerg. Infect.

- 571 *Dis.* **20**, 1009–1011 (2014).
- 572 28. Curaudeau, M. *et al.* Identifying the Most Probable Mammal Reservoir Hosts for Monkeypox Virus
  573 Based on Ecological Niche Comparisons. *Viruses* 15, (2023).
- 574 29. Khodakevich, L., Jezek, Z. & Messinger, D. Monkeypox virus: ecology and public health significance.
- 575 Bull. World Health Organ. **66**, 747–752 (1988).
- 576 30. Nolen, L. D. et al. Introduction of Monkeypox into a Community and Household: Risk Factors and
- 577 Zoonotic Reservoirs in the Democratic Republic of the Congo. *Am. J. Trop. Med. Hyg.* 93, 410–415
  578 (2015).
- 31. Breman, J. G., Bernadou, J. & Nakano, J. H. Poxvirus in West African nonhuman primates: serological
  survey results. *Bull. World Health Organ.* 55, 605–612 (1977).
- 32. Pekar, J. E. *et al.* The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2. *Science*377, 960–966 (2022).
- 33. Glennon, E. E., Jephcott, F. L., Restif, O. & Wood, J. L. N. Estimating undetected Ebola spillovers. *PLoS Negl. Trop. Dis.* 13, e0007428 (2019).
- 585 34. Titanji, B. K. *et al.* Effectiveness of Smallpox Vaccination to Prevent Mpox in Military Personnel. *N.*586 *Engl. J. Med.* 389, 1147–1148 (2023).
- 587 35. Fine, P. E., Jezek, Z., Grab, B. & Dixon, H. The transmission potential of monkeypox virus in human
  588 populations. *Int. J. Epidemiol.* 17, 643–650 (1988).
- 589 36. Rimoin, A. W. et al. Major increase in human monkeypox incidence 30 years after smallpox
- vaccination campaigns cease in the Democratic Republic of Congo. *Proc. Natl. Acad. Sci. U. S. A.* 107,
  16262–16267 (2010).
- 592 37. Median age (years). WHO Data https://platform.who.int/data/maternal-newborn-child-adolescent-
- 593 ageing/indicator-explorer-new/MCA/median-age-(years).
- 594 38. Fa, J. E., Ryan, S. F. & Bell, D. J. Hunting vulnerability, ecological characteristics and harvest rates of
  595 bushmeat species in afrotropical forests. *Biol. Conserv.* 121, 167–176 (2005).
- 39. Silva, N. I. O., de Oliveira, J. S., Kroon, E. G., Trindade, G. de S. & Drumond, B. P. Here, There, and
- 597 Everywhere: The Wide Host Range and Geographic Distribution of Zoonotic Orthopoxviruses. *Viruses*
- **598 13**, (2020).

- 40. Effiom, E. O., Nuñez-Iturri, G., Smith, H. G., Ottosson, U. & Olsson, O. Bushmeat hunting changes
- 600 regeneration of African rainforests. *Proc. Biol. Sci.* 280, 20130246 (2013).
- 41. Macdonald, D. W. et al. Bushmeat trade in the Cross–Sanaga rivers region: Evidence for the
- 602 importance of protected areas. *Biol. Conserv.* **147**, 107–114 (2012).
- 42. Friant, S., Paige, S. B. & Goldberg, T. L. Drivers of bushmeat hunting and perceptions of zoonoses in
  Nigerian hunting communities. *PLoS Negl. Trop. Dis.* 9, e0003792 (2015).
- 43. Fa, J. E. *et al.* Getting to grips with the magnitude of exploitation: Bushmeat in the Cross–Sanaga
  rivers region, Nigeria and Cameroon. *Biol. Conserv.* **129**, 497–510 (2006).
- 607 44. Gessain, A., Nakoune, E. & Yazdanpanah, Y. Monkeypox. N. Engl. J. Med. 387, 1783–1793 (2022).
- 45. Khodakevich, L. *et al.* Monkeypox virus in relation to the ecological features surrounding human
- 609 settlements in Bumba zone, Zaire. *Trop. Geogr. Med.* **39**, 56–63 (1987).
- 46. Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the effect of
  individual variation on disease emergence. *Nature* 438, 355–359 (2005).
- 47. Borges, V. *et al.* Viral genetic clustering and transmission dynamics of the 2022 mpox outbreak in
  Portugal. *Nat. Med.* 29, 2509–2517 (2023).
- 48. Laurenson-Schafer, H. *et al.* Description of the first global outbreak of mpox: an analysis of global
  surveillance data. *The Lancet Global Health* **11**, e1012–e1023 (2023).
- 49. Ulaeto, D. O., Dunning, J. & Carroll, M. W. Evolutionary implications of human transmission of
  monkeypox: the importance of sequencing multiple lesions. *Lancet Microbe* 3, e639–e640 (2022).
- 50. Nigeria Centre for Disease Control. National monkeypox public health response guidelines. Preprint
- at https://ncdc.gov.ng/themes/common/docs/protocols/96\_1577798337.pdf.
- 620 51. Park, D. et al. Broadinstitute/viral-Ngs: v1.19.2. (Zenodo, 2018). doi:10.5281/zenodo.1167849.
- 52. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* 25, 1754–1760 (2009).
- 53. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079
  (2009).
- 54. Grubaugh, N. D. et al. An amplicon-based sequencing framework for accurately measuring intrahost
- 626 virus diversity using PrimalSeq and iVar. *Genome Biol.* **20**, 8 (2019).

- 55. Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the
  Genomic Era. *Mol. Biol. Evol.* 37, 1530–1534 (2020).
- 629 56. Aksamentov, I., Roemer, C., Hodcroft, E. & Neher, R. Nextclade: clade assignment, mutation calling
- and quality control for viral genomes. J. Open Source Softw. **6**, 3773 (2021).
- 57. Suchard, M. A. *et al.* Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol* 4, vey016 (2018).
- 58. Ayres, D. L. et al. BEAGLE 3: Improved Performance, Scaling, and Usability for a High-Performance
- 634 Computing Library for Statistical Phylogenetics. *Syst. Biol.* 68, 1052–1061 (2019).
- 635 59. Rambaut, A., Drummond, A. J., Xie, D., Baele, G. & Suchard, M. A. Posterior summarization in
- Bayesian phylogenetics using tracer 1.7. Syst. Biol. 67, 901–904 (2018).
- 637 60. Tavaré, S. Some probabilistic and statistical problems in the analysis of DNA sequences. Some
   638 mathematical guestion in biology-DNA (1986).
- 639 61. Zuckerkandl, E. Molecular disease, evolution, and genic heterogeneity. *Horiz. Biochem. Biophys.*640 (1962).
- 641 62. Yoder, A. D. & Yang, Z. Estimation of primate speciation dates using local molecular clocks. *Mol. Biol.*
- 642 Evol. **17**, 1081–1090 (2000).
- 643 63. Ferreira, M. A. R. & Suchard, M. A. Bayesian analysis of elapsed times in continuous-time Markov
- 644 chains. Can. J. Stat. **36**, 355–368 (2008).
- 645 64. Baele, G., Lemey, P. & Suchard, M. A. Genealogical Working Distributions for Bayesian Model Testing
  646 with Phylogenetic Uncertainty. *Syst. Biol.* 65, 250–264 (2016).
- 647 65. Xie, W., Lewis, P. O., Fan, Y., Kuo, L. & Chen, M.-H. Improving marginal likelihood estimation for
- Bayesian phylogenetic model selection. Syst. Biol. 60, 150–160 (2011).

### 649 Acknowledgements

This work is made possible by support from Flu Lab and a cohort of generous donors through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll Foundation, and Open Philanthropy. This work was supported by the Centre Pasteur of Cameroon. This work was supported by grants from the National Institute of Allergy and Infectious Diseases grants U01HG007480 (H3Africa), U54HG007480 655 (H3Africa), U01AI151812 (WARN-ID), U19AI135995 (CViSB), U19AI110818 (GCID), 656 R01AI153044 and R01AI162611). This work was also supported by the World Bank grants projects ACE-019 and ACE-IMPACT; The Rockefeller Foundation (Grant #2021 657 658 HTH); The Africa CDC through the African Society of Laboratory Medicine [ASLM] (Grant #INV018978), and the Science for Africa Foundation. We thank the Africa CDC for Mpox 659 660 diagnostic reagents provided to the surveillance system in Cameroon. We thank Advanced Micro Devices, Inc. for the donation of massively parallel computing hardware. 661 662 Ifeanyi Omah is supported by the Wellcome Trust Hosts, Pathogens & Global Health program [Wellcome Trust, Grant number 218471/Z/19/Z] in partnership with Tackling 663 664 infectious Disease to Benefit Africa, TIBA.

### 665 Author Contributions

666 C.H., R.N., P.S., I.J., I.A. conceptualized the study. D.D.D., I.F.O., E.P., A.O.T., M.A.S., 667 P.L., K.G.A., A.R., C.H. contributed the methodology. K.G., A.O.T., P.L., M.A.S., A.R.,

- P.L., K.G.A., A.R., C.H. contributed the methodology. K.G., A.O.T., P.L., M.A.S., A.R.,
   P.V. provided software. D.D.D, I.F.O., E.P. performed formal analysis. D.D.D., I.F.O.,
- 669 E.P., L.L.M.E, M.H.M.Y, F.M.F.C, A.O.A., A.E.S, M.I.A., O.O.E, O.A.O., A.O., P.E.,
- 670 O.A., A.E., O.E., C.C., K.S., A.Akinpelu, A.Ahmad, K.I.I., P.V., A.M., M.Z., A.R. M.G.Y.
- 671 G.D.E., I.P.T., L.M., S.I.E., L.E., I.M.E.N., S.F.M., C.C., S.M.A., H.M.M., C.N.B.,
- A.G.M.E. conducted the investigation. D.D.D., L.L.M.E, M.H.M.Y, F.M.F.C, A.O.A,
- 673 A.E.S, M.I.A., O.O.E, O.A.O, A.O., P.E., O.A., A.E., O.E., C.C, K.S., A.Akinpelu,
- 674 A.Ahmad, K.I.I., D.J.P, P.L., G.M., S.K.T., Y.K.T., O.F., A.H., M.A.S., K.G.A., A.R., R.N.,
- 675 C.I., I.J., I.A., S.I.E., provided resources. E.P., I.F.O., D.D.D., A.R., C.T.T., J.R.O.
- 676 curated data. E.P., I.F.O., D.D.D wrote the original draft of the manuscript. All authors
- 677 reviewed and edited the manuscript. I.F.O., E.P. performed visualization. R.N., C.H.,
- 678 C.I., I.J., I.A., P.S., A.R., K.G.A supervised the study. D.D.D., S.I.E., E.P., O.F., C.H. 679 undertook project administration. C.H., P.S., R.N., S.I.E., K.G.A. acquired funding.

680

### 681 Competing interest declaration

682 MAS received grants and contracts from the U.S. Food & Drug Administration, the U.S.

- 683 Department of Veterans Affairs and Johnson & Johnson outside the scope of this work.
- 684

685

### 686 Extended Data



687

688 Extended Data Figure 1: Estimates of the evolutionary rate for zoonotic Clade IIb and
 689 Clade IIa combined under the different clock models
 690

691 Extended Data table 1: Model testing for analyses of evolutionary rate in the natural reservoir

Model	Clock rate (95% HPD x10 <sup>-6</sup> )	Cladell tMRCA	Log MLE	Log BF
FLC	4.29(3.11–5.55)	May 30, 1908, (July 6, 1886, to February 24, 1928)	-259654.2406	
FLC	2.02(1.45–2.59)	October 20, 1542, (June 18, 1401, to October 7, 1664)	-259654.2406	_
SC	2.49(1.90–3.10)	April 27, 1624, (April 15, 1523, to October 30, 1712)	-259843.2503	189.01 vs FLC
UCL	3.33(1.76–6.19)	May 24, 1669, (April 17, 1410, to November 18, 1892)	-259858.1452	203.905 vs FLC

692